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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Discuss the history of clinical trials using surgery, radiation, and chemotherapy in head and neck cancer.
2. Explain the benefit of chemoradiotherapy in locally advanced head and neck cancer.
3. Describe the role of adjuvant chemotherapy with cisplatin and 5-FU followed by chemoradiation with or without
taxanes.
4. Evaluate the toxicity of adding taxanes and the need for further clinical trials adding taxanes.
Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comCME
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
In recent years, we have faced the argument that sequential
therapy with the combination of a taxane, a platinum, and
5-fluorouracil (5-FU) (TPF), followed by concurrent che-
moirradiation, represents a new acceptable standard of care
for locally advanced head and neck (HN) cancer. This ar-
gument is based on two premises: (a) previous data showing
the superiority of induction chemotherapy containing cis-
platin and 5-FU (PF) followed by radiotherapy over radio-
therapy alone, and (b) recent data demonstrating the
superiority of induction with TPF over induction with PF.
However, both the theoretical basis and the clinical evi-
dence supporting induction chemotherapy are weak. Until
current randomized studies that compare induction TPF fol-
lowed by chemoradiotherapy (CRT) with CRT alone are
concluded, there is yet no evidence for the superiority of in-
duction chemotherapy. The announcement about a “new
standard of care” is, therefore, premature.
HISTORICAL OVERVIEW
The theoretical basis for induction chemotherapy was de-
veloped in the early 1980s. As high response rates were ob-
served and data were presented suggesting that those who
respond are more likely to achieve tumor control, induction
chemotherapy spread rapidly in the community. In 1997, a
survey of community oncologists found that the single most
common treatment approach for patients with locoregional
advanced HN cancer was that of induction PF followed by
radiotherapy, even though randomized studies and meta-
analyses published at the time had not shown any locore-
gional or survival advantage over radiotherapy alone [1].
Notably, 96% of responders indicated that induction PF
was not delivered as part of a clinical study. Ten years later,
we are facing a similar scenario: induction TPF chemother-
apy followed by concurrent CRT is advertised to the com-
munity as a new standard of care, while several randomized
studies that have specifically been devised to test its supe-
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riority over concurrent CRT are ongoing and their results
are not yet known.
BIOLOGICAL AND CLINICAL CONSIDERATIONS
There are several biological and clinical reasons, detailed
below, that suggest that induction TPF followed by CRT
may fail to improve outcome over CRT alone.
Chemotherapy alone is not curative, even in the best cir-
cumstances. We have appreciated this in a recent study in
which six cycles of PF chemotherapy were delivered, with-
out radiotherapy, for patients with laryngeal cancer who
achieved biopsy-proven complete response after one cycle
of induction PF [2]. The hypothesis was that these patients,
representing only 10%–15% of the patients with locally ad-
vanced laryngeal cancer, had been selected as the best re-
sponders to chemotherapy and they may achieve cure with
chemotherapy alone, avoiding the toxicity of radiotherapy.
All these patients failed locoregionally, prompting discon-
tinuation of the study [2]. The failure of chemotherapy de-
livered without concomitant radiotherapy to impact
eventual outcome was previously predicted by Ian Tannock
[3]. If a 10-g tumor containing 1010 cells is treated with
three cycles of induction chemotherapy, each of which kills
50%–90% of the tumor cells, after three cycles, the number
of viable cells is close to 108 (0.1 g) and the patient is as-
sumed to achieve clinical and radiological complete remis-
sion. However, cell reduction has been trivial: we are still
facing close to 108 cells. Moreover, additional chemother-
apy may not be helpful if drug-resistant cells have been se-
lected after three courses of chemotherapy.
The shrinkage of the tumor after induction chemother-
apy, even if it has been substantial, is not likely to help the
radiation oncologist in defining a smaller target volume and
sparing more noninvolved tissue. Tissue volumes from
which the tumor has shrunk radiographically may still con-
tain a large number of tumor cells that are at the threshold of
our ability to detect radiologically. Sparing these tissues
may be detrimental. The clinical experience of local fail-
ures in all patients receiving chemotherapy alone, even if
radiological and histological complete response has been
achieved, as well as prudence, dictate that preinduction tu-
mor volumes should be targeted by radiotherapy. No bene-
fit is expected to be gained in this regard.
Another biological consideration is the accelerated re-
population of surviving tumor clonogens that occurs during
an extended total treatment time [4]. Most clinical and pre-
clinical data suggest that accelerated repopulation occurs
toward the end of a fractionated radiotherapy course; how-
ever, this phenomenon is not exclusive to radiotherapy. The
delivery of three cycles of induction chemotherapy extends
the total treatment time by approximately 9 weeks. The de-
finitive therapy (CRT) is delivered after a lengthy course of
therapy that reduces tumor volume but does not eliminate it,
causing accelerated repopulation of surviving clonogens
even before CRT is started, rather than at the end of the
CRT course. This poses a theoretical impediment to the pa-
tient’s chance of cure.
The most important clinical consideration, apart from
the toxicity of the induction therapy (induction TPF had a
toxic death rate of 3.7% even before CRT was started [5]),
is the fact that a certain number of patients receiving induc-
tion chemotherapy do not proceed to receive definitive ther-
apy. The causes for omitting definitive therapy include the
toxicity of induction or patient refusal to proceed with CRT
after the bulk of their disease has been reduced by induction
chemotherapy. Early randomized studies of induction che-
motherapy followed by standard local treatment versus ra-
diotherapy alone reported that, while toxicity to chemo-
therapy was not a factor in survival, the number of patients
who withdrew from the studies and those who did not com-
ply with treatment were greater in the chemotherapy
groups, which was the likely cause of an inferior outcome
of patients receiving induction chemotherapy [6].
Rosenthal et al. [4] noted that this phenomenon is similar to
that faced by a surgeon following an excisional biopsy of
tumor: the patient may query why more treatment is re-
quired, because all visible tumor has been removed.
Patient attrition during or after induction chemotherapy
is not confined to earlier studies. Hitt et al. [7] recently re-
ported the results of a randomized study for advanced HN
cancer comparing induction using carboplatin and 5-FU
(CF) with induction using paclitaxel plus CF (PCF), fol-
lowed in both arms by CRT. The results showed that PCF
was better tolerated and resulted in a higher complete re-
sponse rate than with CF. A detailed flowsheet of patient
numbers in each phase of the study was provided (Figure 2
in the paper). In the PCF arm, 9 of 189 (5%) patients
dropped out during PCF chemotherapy. In addition, of 129
patients achieving a partial or complete response who were
eligible to proceed with CRT, an additional 15 patients
(12%) dropped out and did not receive definitive therapy.
Thus, 13% of the patients assigned for the better-tolerated
PCF induction regimen dropped out and did not receive the
definitive treatment. This rate was even higher in the less
well-tolerated CF arm. These high rates of dropout may ex-
plain the differences in outcome between the two arms. Fur-
thermore, at least some of these patients would likely have
completed their definitive therapy had induction chemo-
therapy not been delivered. Taking into account the fact that
this was a prospective, randomized study, where diligent
data acquisition and patient follow-up were likely per-
formed by study coordinators, can these dropout rates be
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even higher outside study, and in the community, where
96% of HN cancer patients are treated? The answer is
most probably, yes. These dropout rates, in addition to toxic
deaths, are likely to negate any potential benefit offered by
induction chemotherapy.
CONCLUSIONS
These biological and clinical shortcomings of induction
chemotherapy are reflected by the large majority of the ran-
domized studies in HN cancer. These studies demonstrated
no or marginal benefit of cisplatin-containing induction
chemotherapy over radiotherapy alone regarding locore-
gional control, disease-free survival, or survival, and are
cited in recent meta-analyses [8, 9]. Conveniently, propo-
nents of induction chemotherapy often cite the only two
randomized studies showing a benefit of induction chemo-
therapy, ignoring the many studies that have demonstrated
no benefit [5].
It is possible that the advantages of taxane-containing
chemotherapy over CF are large enough to overcome the
lack of benefit of induction chemotherapy reported to date.
Several randomized studies of taxane-containing induction
chemotherapy followed by CRT, versus CRT alone, are
currently ongoing. The results of these studies will be
known in the near future. Until these results are known, the
superiority of induction TPF chemotherapy followed by
CRT over CRT is still a hypothesis. The claim that this is a
new standard of care is baseless, for the time being. Propos-
ing it to the community at this time, without presenting the
potential downside of induction chemotherapy and the lack
of current evidence for its superiority over CRT alone, is
problematic.
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